Predictive Potential of Biomarkers of Intestinal Barrier Function for Therapeutic Management with Teduglutide in Patients with Short Bowel Syndrome
Introduction: The human intestinal tract reacts to extensive resection with spontaneous intestinal adaptation. We analyzed whether gene expression analyses or intestinal permeability (IP) testing could provide biomarkers to describe regulation mechanisms in the intestinal barrier in short bowel synd...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | Nutrients |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6643/15/19/4220 |
| _version_ | 1797575415222501376 |
|---|---|
| author | Janine Büttner Elisabeth Blüthner Sophie Greif Anja Kühl Sefer Elezkurtaj Jan Ulrich Sebastian Maasberg Christoph Jochum Frank Tacke Ulrich-Frank Pape |
| author_facet | Janine Büttner Elisabeth Blüthner Sophie Greif Anja Kühl Sefer Elezkurtaj Jan Ulrich Sebastian Maasberg Christoph Jochum Frank Tacke Ulrich-Frank Pape |
| author_sort | Janine Büttner |
| collection | DOAJ |
| description | Introduction: The human intestinal tract reacts to extensive resection with spontaneous intestinal adaptation. We analyzed whether gene expression analyses or intestinal permeability (IP) testing could provide biomarkers to describe regulation mechanisms in the intestinal barrier in short bowel syndrome (SBS) patients during adaptive response or treatment with the glucagon-like peptide-2 analog teduglutide. Methods: Relevant regions of the GLP-2 receptor gene were sequenced. Gene expression analyses and immunohistochemistry were performed from mucosal biopsies. IP was assessed using a carbohydrate oral ingestion test. Results: The study includes 59 SBS patients and 19 controls. Increases in gene expression with teduglutide were received for sucrase-isomaltase, sodium/glucose cotransporter 1, and calcium/calmodulin serine protein kinase. Mannitol recovery was decreased in SBS but elevated with teduglutide (Δ 40%), showed a positive correlation with remnant small bowel and an inverse correlation with parenteral support. Conclusions: Biomarkers predicting clinical and functional features in human SBS are very limited. Altered specific gene expression was shown for genes involved in nutrient transport but not for genes controlling tight junctions. However, mannitol recovery proved useful in describing the absorptive capacity of the gut during adaptation and treatment with teduglutide. |
| first_indexed | 2024-03-10T21:38:13Z |
| format | Article |
| id | doaj.art-e417db28f76b45a58f4977d202090119 |
| institution | Directory Open Access Journal |
| issn | 2072-6643 |
| language | English |
| last_indexed | 2024-03-10T21:38:13Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Nutrients |
| spelling | doaj.art-e417db28f76b45a58f4977d2020901192023-11-19T14:51:52ZengMDPI AGNutrients2072-66432023-09-011519422010.3390/nu15194220Predictive Potential of Biomarkers of Intestinal Barrier Function for Therapeutic Management with Teduglutide in Patients with Short Bowel SyndromeJanine Büttner0Elisabeth Blüthner1Sophie Greif2Anja Kühl3Sefer Elezkurtaj4Jan Ulrich5Sebastian Maasberg6Christoph Jochum7Frank Tacke8Ulrich-Frank Pape9Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Hepatology and Gastroenterology, Campus Charité Mitte and Campus Virchow Klinikum, 10117 Berlin, GermanyCharité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Hepatology and Gastroenterology, Campus Charité Mitte and Campus Virchow Klinikum, 10117 Berlin, GermanyCharité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Hepatology and Gastroenterology, Campus Charité Mitte and Campus Virchow Klinikum, 10117 Berlin, GermanyiPATH.Berlin, Core Unit der Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt, Campus Benjamin Franklin, 12203 Berlin, GermanyCharité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Pathology, Campus Mitte, 10117 Berlin, GermanyDepartment of Internal Medicine and Gastroenterology, Asklepios Klinik St. Georg, 20099 Hamburg, GermanyDepartment of Internal Medicine and Gastroenterology, Asklepios Klinik St. Georg, 20099 Hamburg, GermanyCharité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Hepatology and Gastroenterology, Campus Charité Mitte and Campus Virchow Klinikum, 10117 Berlin, GermanyCharité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Hepatology and Gastroenterology, Campus Charité Mitte and Campus Virchow Klinikum, 10117 Berlin, GermanyCharité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Hepatology and Gastroenterology, Campus Charité Mitte and Campus Virchow Klinikum, 10117 Berlin, GermanyIntroduction: The human intestinal tract reacts to extensive resection with spontaneous intestinal adaptation. We analyzed whether gene expression analyses or intestinal permeability (IP) testing could provide biomarkers to describe regulation mechanisms in the intestinal barrier in short bowel syndrome (SBS) patients during adaptive response or treatment with the glucagon-like peptide-2 analog teduglutide. Methods: Relevant regions of the GLP-2 receptor gene were sequenced. Gene expression analyses and immunohistochemistry were performed from mucosal biopsies. IP was assessed using a carbohydrate oral ingestion test. Results: The study includes 59 SBS patients and 19 controls. Increases in gene expression with teduglutide were received for sucrase-isomaltase, sodium/glucose cotransporter 1, and calcium/calmodulin serine protein kinase. Mannitol recovery was decreased in SBS but elevated with teduglutide (Δ 40%), showed a positive correlation with remnant small bowel and an inverse correlation with parenteral support. Conclusions: Biomarkers predicting clinical and functional features in human SBS are very limited. Altered specific gene expression was shown for genes involved in nutrient transport but not for genes controlling tight junctions. However, mannitol recovery proved useful in describing the absorptive capacity of the gut during adaptation and treatment with teduglutide.https://www.mdpi.com/2072-6643/15/19/4220short bowel syndromechronic intestinal failureglucagon-like peptide-2teduglutideintestinal permeability |
| spellingShingle | Janine Büttner Elisabeth Blüthner Sophie Greif Anja Kühl Sefer Elezkurtaj Jan Ulrich Sebastian Maasberg Christoph Jochum Frank Tacke Ulrich-Frank Pape Predictive Potential of Biomarkers of Intestinal Barrier Function for Therapeutic Management with Teduglutide in Patients with Short Bowel Syndrome Nutrients short bowel syndrome chronic intestinal failure glucagon-like peptide-2 teduglutide intestinal permeability |
| title | Predictive Potential of Biomarkers of Intestinal Barrier Function for Therapeutic Management with Teduglutide in Patients with Short Bowel Syndrome |
| title_full | Predictive Potential of Biomarkers of Intestinal Barrier Function for Therapeutic Management with Teduglutide in Patients with Short Bowel Syndrome |
| title_fullStr | Predictive Potential of Biomarkers of Intestinal Barrier Function for Therapeutic Management with Teduglutide in Patients with Short Bowel Syndrome |
| title_full_unstemmed | Predictive Potential of Biomarkers of Intestinal Barrier Function for Therapeutic Management with Teduglutide in Patients with Short Bowel Syndrome |
| title_short | Predictive Potential of Biomarkers of Intestinal Barrier Function for Therapeutic Management with Teduglutide in Patients with Short Bowel Syndrome |
| title_sort | predictive potential of biomarkers of intestinal barrier function for therapeutic management with teduglutide in patients with short bowel syndrome |
| topic | short bowel syndrome chronic intestinal failure glucagon-like peptide-2 teduglutide intestinal permeability |
| url | https://www.mdpi.com/2072-6643/15/19/4220 |
| work_keys_str_mv | AT janinebuttner predictivepotentialofbiomarkersofintestinalbarrierfunctionfortherapeuticmanagementwithteduglutideinpatientswithshortbowelsyndrome AT elisabethbluthner predictivepotentialofbiomarkersofintestinalbarrierfunctionfortherapeuticmanagementwithteduglutideinpatientswithshortbowelsyndrome AT sophiegreif predictivepotentialofbiomarkersofintestinalbarrierfunctionfortherapeuticmanagementwithteduglutideinpatientswithshortbowelsyndrome AT anjakuhl predictivepotentialofbiomarkersofintestinalbarrierfunctionfortherapeuticmanagementwithteduglutideinpatientswithshortbowelsyndrome AT seferelezkurtaj predictivepotentialofbiomarkersofintestinalbarrierfunctionfortherapeuticmanagementwithteduglutideinpatientswithshortbowelsyndrome AT janulrich predictivepotentialofbiomarkersofintestinalbarrierfunctionfortherapeuticmanagementwithteduglutideinpatientswithshortbowelsyndrome AT sebastianmaasberg predictivepotentialofbiomarkersofintestinalbarrierfunctionfortherapeuticmanagementwithteduglutideinpatientswithshortbowelsyndrome AT christophjochum predictivepotentialofbiomarkersofintestinalbarrierfunctionfortherapeuticmanagementwithteduglutideinpatientswithshortbowelsyndrome AT franktacke predictivepotentialofbiomarkersofintestinalbarrierfunctionfortherapeuticmanagementwithteduglutideinpatientswithshortbowelsyndrome AT ulrichfrankpape predictivepotentialofbiomarkersofintestinalbarrierfunctionfortherapeuticmanagementwithteduglutideinpatientswithshortbowelsyndrome |